# Bruker Corporation (BRKR) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Technology. Price $58.50, market value $8.9 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Bruker Corporation reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 2.5×**. Each dollar of revenue is priced at 2.5×.
- **Price / book: 3.7×**. The shares trade at 3.7× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 52.5×**. Enterprise value is 52.5× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 1.1%** (5-yr avg 1.5%). Free cash flow equals 1.1% of the market value, below its five-year average of 1.5%, so the shares are pricier on cash than usual.

## Profitability
- **Gross margin: 46.4%**. Bruker Corporation keeps 46.4% of revenue after the direct cost of what it sells.
- **Operating margin: -0.9%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -0.3%**. The company reported a net loss over the last twelve months.
- **Return on equity: -0.4%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -0.6%**. Return on all capital, debt included, is -0.6%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -1.1%**. Each dollar of assets produces -1.1% of profit.

## Growth
- **Revenue growth (1 yr): 2.1%** (3-yr 10.7%/yr, 5-yr 11.6%/yr). Revenue grew 2.1% over the last year, against 11.6% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -119.7%**. Earnings per share fell 119.7%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): -33.2%/yr**. Free cash flow has compounded at -33.2% a year over three years.

## Financial health
- **Debt to equity: 0.75**. Debt is 0.75 times equity, moderate leverage.
- **Net debt / EBITDA: 7.8×**. It would take 7.8 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Altman Z-score: 2.57**. A Z-score of 2.57 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend yield: 0.34%** ($0.20 per share, trailing). Bruker Corporation yields 0.34%, a modest yield more typical of a growth-oriented payer.
- **Consecutive years of increases: 10**. 10 straight years of increases, a record that survived at least one recession.
- **Dividend growth (5 yr): 4.6%/yr** (1-yr 0.0%). The dividend has grown 4.6% a year over five years.

## Price and momentum
- **Total return (1 yr): 97.3%** (YTD 24.5%, 3-mo 3.8%). The shares are up 97.3% over twelve months including dividends.
- **From 52-week high: -10.4%** (94.4% above the low). Trading 10% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 51**. An RSI of 51 is neutral.
- **Beta (1 yr): 1.37** (volatility 56%). Beta of 1.37 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BRKR · Page: https://foliofundamentals.com/stocks/brkr

Not investment advice.